pteridines has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nieto-Jimenez, C | 1 |
| Galan-Moya, EM | 1 |
| Corrales-Sanchez, V | 1 |
| Noblejas-Lopez, MDM | 1 |
| Burgos, M | 1 |
| Domingo, B | 1 |
| Montero, JC | 1 |
| Gomez-Juarez, M | 1 |
| Picazo-Martinez, MG | 1 |
| Esparis-Ogando, A | 1 |
| Pandiella, A | 1 |
| Ocaña, A | 1 |
| Davies, AH | 1 |
| Reipas, K | 1 |
| Hu, K | 1 |
| Berns, R | 1 |
| Firmino, N | 1 |
| Stratford, AL | 1 |
| Dunn, SE | 1 |
2 other studies available for pteridines and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.
Topics: Animals; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; G2 Phas | 2020 |
Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Neoplast | 2015 |